Reg. 34 (1) Annual Report.
Filed with BSE · · 154 pages · English
Welcure Drugs and Pharmaceuticals Ltd. on 6ix
Story so far
- Standalone Unaudited Financial Results For The 1St Quarter Ended 30Th June 2025
- Audited Standalone Financial Results And Audited Standalone Financial Statements Along With Auditor'S Report Of The Company For The Quarter And Year Ended March 31, 2025
- Unaudited Financial Results Of The Company Along With TheLimited Review Report As Issued By Statutory Auditor Of The Company For The 2Nd Quarter And HalfYear Ended On 30Th September 2024.
Earlier from Welcure Drugs and Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Change in Management
- Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Announcement/Information Under Regulation 44 Of SEBI (LODR) Regulations, 2015 Regarding Providing Remote E-Voting Facilities For The Of Annual General Meeting To BeHeld On 27" Septembers, 2025.
- Corporate Announcement/Information Under Regulation 42 Of SEBI (LODR) Regulations, 2015 Regarding Book Closure And Intimation Of Date Of The 33Rd Annual General Meeting.
- Board Meeting Outcome for Outcome Of Meeting Of The Board Of Directors Under The Regulation 29 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations,2015.
Later from Welcure Drugs and Pharmaceuticals
- Notice Of 33Rd Annual General Meeting Of Welcure Drugs & Pharmaceuticals Limited
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Sep 02 2025
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Welcure Drugs And Pharmaceuticals Ltd. Press Release Sep 03 2025
- Board Meeting Intimation for To Take On Record And Deliberate Upon The Letter Of Intent (LOI) Received From Telexcell Trade PTE LTD, Singapore
Follow Welcure Drugs and Pharmaceuticals into a list and get an email when it puts out news.
Follow Welcure Drugs and Pharmaceuticals